Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Increases By 8.5%

Atyr PHARMA INC (NASDAQ:ATYR) saw a significant increase in short interest in January. As of January 31st, there was short interest totalling 3,820,000 shares, an increase of 8.5% from the January 15th total of 3,520,000 shares. Approximately 4.7% of the company’s stock are sold short. Based on an average trading volume of 820,000 shares, the short-interest ratio is currently 4.7 days.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ATYR shares. Leerink Partners started coverage on shares of Atyr PHARMA in a research report on Tuesday. They set an “outperform” rating and a $16.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Atyr PHARMA presently has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Stock Down 5.0 %

Atyr PHARMA stock opened at $3.41 on Tuesday. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.22. The firm has a 50 day moving average price of $3.55 and a 200-day moving average price of $2.82. The company has a market capitalization of $286.24 million, a P/E ratio of -3.63 and a beta of 1.10. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Institutional Trading of Atyr PHARMA

A number of institutional investors have recently modified their holdings of the business. Group One Trading LLC purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $26,000. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $36,000. Victory Capital Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $37,000. Raymond James Financial Inc. purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $39,000. Finally, XTX Topco Ltd purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $40,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.